CL2023003048A1 - Anticuerpos anti-cd122 y usos de estos - Google Patents

Anticuerpos anti-cd122 y usos de estos

Info

Publication number
CL2023003048A1
CL2023003048A1 CL2023003048A CL2023003048A CL2023003048A1 CL 2023003048 A1 CL2023003048 A1 CL 2023003048A1 CL 2023003048 A CL2023003048 A CL 2023003048A CL 2023003048 A CL2023003048 A CL 2023003048A CL 2023003048 A1 CL2023003048 A1 CL 2023003048A1
Authority
CL
Chile
Prior art keywords
antibody molecules
antibodies
molecules
antigen
vectors
Prior art date
Application number
CL2023003048A
Other languages
English (en)
Spanish (es)
Inventor
James Jonathan Finlay William
e harris John
Original Assignee
Villaris Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Villaris Therapeutics Inc filed Critical Villaris Therapeutics Inc
Publication of CL2023003048A1 publication Critical patent/CL2023003048A1/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6849Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0014Skin, i.e. galenical aspects of topical compositions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/06Immunosuppressants, e.g. drugs for graft rejection
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/63Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/505Medicinal preparations containing antigens or antibodies comprising antibodies
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/20Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/30Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/30Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/30Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/35Valency
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/50Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/50Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565Complementarity determining region [CDR]
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/90Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Wood Science & Technology (AREA)
  • Dermatology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Zoology (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Transplantation (AREA)
  • Physics & Mathematics (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CL2023003048A 2021-04-14 2023-10-12 Anticuerpos anti-cd122 y usos de estos CL2023003048A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202163174772P 2021-04-14 2021-04-14
US202163279762P 2021-11-16 2021-11-16

Publications (1)

Publication Number Publication Date
CL2023003048A1 true CL2023003048A1 (es) 2024-04-12

Family

ID=81579792

Family Applications (2)

Application Number Title Priority Date Filing Date
CL2023003048A CL2023003048A1 (es) 2021-04-14 2023-10-12 Anticuerpos anti-cd122 y usos de estos
CL2024002847A CL2024002847A1 (es) 2021-04-14 2024-09-24 Anticuerpos anti-cd122 y usos de estos.

Family Applications After (1)

Application Number Title Priority Date Filing Date
CL2024002847A CL2024002847A1 (es) 2021-04-14 2024-09-24 Anticuerpos anti-cd122 y usos de estos.

Country Status (19)

Country Link
US (2) US20230357420A1 (https=)
EP (1) EP4323402A1 (https=)
JP (1) JP2024513921A (https=)
KR (1) KR20230170672A (https=)
AU (1) AU2022256455A1 (https=)
BR (1) BR112023021297A2 (https=)
CA (1) CA3215058A1 (https=)
CL (2) CL2023003048A1 (https=)
CO (1) CO2023015254A2 (https=)
CR (1) CR20230523A (https=)
DO (1) DOP2023000211A (https=)
EC (1) ECSP23085780A (https=)
GE (3) GEAP202316382A (https=)
IL (1) IL307267A (https=)
JO (1) JOP20230246A1 (https=)
MX (1) MX2023012218A (https=)
PE (1) PE20240086A1 (https=)
PH (1) PH12023552784A1 (https=)
WO (1) WO2022221409A1 (https=)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2024040194A1 (en) 2022-08-17 2024-02-22 Capstan Therapeutics, Inc. Conditioning for in vivo immune cell engineering
JP2025537224A (ja) * 2022-11-07 2025-11-14 アナプティスバイオ インコーポレイティッド Cd122結合剤およびその使用方法
AU2024279278A1 (en) 2023-05-31 2025-12-18 Capstan Therapeutics, Inc. Lipid nanoparticle formulations and compositions
US20250127728A1 (en) 2023-10-05 2025-04-24 Capstan Therapeutics, Inc. Constrained Ionizable Cationic Lipids and Lipid Nanoparticles
WO2025076113A1 (en) 2023-10-05 2025-04-10 Capstan Therapeutics, Inc. Ionizable cationic lipids with conserved spacing and lipid nanoparticles
US20250302763A1 (en) 2024-02-22 2025-10-02 Capstan Therapeutics, Inc. Immune engineering amplification
WO2025217452A1 (en) 2024-04-11 2025-10-16 Capstan Therapeutics, Inc. Constrained ionizable cationic lipids and lipid nanoparticles
WO2025217454A2 (en) 2024-04-11 2025-10-16 Capstan Therapeutics, Inc. Ionizable cationic lipids and lipid nanoparticles

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8308235D0 (en) 1983-03-25 1983-05-05 Celltech Ltd Polypeptides
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
US4975369A (en) 1988-04-21 1990-12-04 Eli Lilly And Company Recombinant and chimeric KS1/4 antibodies directed against a human adenocarcinoma antigen
EP0368684B2 (en) 1988-11-11 2004-09-29 Medical Research Council Cloning immunoglobulin variable domain sequences.
IL162181A (en) 1988-12-28 2006-04-10 Pdl Biopharma Inc A method of producing humanized immunoglubulin, and polynucleotides encoding the same
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
EP2560994B1 (en) * 2010-04-08 2016-10-12 JN Biosciences LLC Antibodies to cd122

Also Published As

Publication number Publication date
GEP20257805B (en) 2025-10-10
JOP20230246A1 (ar) 2023-10-11
AU2022256455A1 (en) 2023-10-12
KR20230170672A (ko) 2023-12-19
AU2022256455A9 (en) 2023-10-26
WO2022221409A1 (en) 2022-10-20
DOP2023000211A (es) 2024-01-15
CR20230523A (es) 2024-01-23
GEAP202316382A (en) 2023-12-25
CA3215058A1 (en) 2022-10-20
PE20240086A1 (es) 2024-01-16
US20230357420A1 (en) 2023-11-09
CL2024002847A1 (es) 2025-01-10
CO2023015254A2 (es) 2023-11-20
JP2024513921A (ja) 2024-03-27
BR112023021297A2 (pt) 2023-12-12
EP4323402A1 (en) 2024-02-21
US20230322944A1 (en) 2023-10-12
GEAP202416574A (en) 2024-09-10
MX2023012218A (es) 2023-12-15
PH12023552784A1 (en) 2024-04-15
ECSP23085780A (es) 2024-01-31
IL307267A (en) 2023-11-01

Similar Documents

Publication Publication Date Title
CL2024002847A1 (es) Anticuerpos anti-cd122 y usos de estos.
BR112022014667A2 (pt) Anticorpos de domínio único de cd28 e construtos multivalentes e multiespecíficos dos mesmos
BR112022013236A2 (pt) Anticorpos anti-cd73 e usos dos mesmos
CO2018012415A2 (es) Proteínas de unión específica y usos de las mismas
EA201791961A1 (ru) Антитела, специфичные к cd47 и pd-l1
BR112023005674A2 (pt) Construtos anti-cd93 e usos dos mesmos
PE20230160A1 (es) Anticuerpos especificos para cd47, pd-l1 y sus usos
MX2022001049A (es) Proteínas que comprenden dominios de unión al antígeno de la peptidasa 2 relacionada con la calicreína y sus usos.
ECSP23053070A (es) Anticuerpos multiespecíficos con especificidad para il-4r e il-31
MX2024014591A (es) Anticuerpo anti-bdca2 y uso del mismo
BR112022017174A2 (pt) Anticorpo monoclonal isolado, ou uma porção de ligação ao antígeno do mesmo, nucleotídeo, vetor de expressão, célula hospedeira, composição farmacêutica e métodos de tratamento de uma doença alérgica e de um tumor
BR112022024629A2 (pt) Construtos anti-cd93 e seus usos
CL2022000096A1 (es) Anticuerpos anti-tigit y aplicación de los mismos
CL2012002662A1 (es) Anticuerpos bivalentes biespecificos anti-veg y un segundo sitio de unión a antígeno que se une específicamente a ang-2 humana; composicion farmacéutica que comprende dicho anticuerpo; método de tratamiento de un paciente que sufre cancer; acido nucleico codificante de dicho anticuerpo, vector de expresión y célula huesped que contiene dicho ácido nucleico.
PE20151613A1 (es) Construcciones de anticuerpos para cdh19 y cd3
BR112022019129A2 (pt) Anticorpos de ligação a siglec15 e usos dos mesmos
CL2019002894A1 (es) Anticuerpo monoclonal para pd-l1.
CL2020001334A1 (es) Anticuerpos que se unen a la proteína de envoltura del virus zika y usos de los mismos. (divisional solicitud 201900999)
CL2022002766A1 (es) Anticuerpos anti-phf-pau y sus usos.
CO2024017318A2 (es) Variantes il-12, anticuerpos anti-pd1, proteínas de fusión y usos de estos
MX2023003644A (es) Constructos de anti-esclerostina y usos de los mismos.
BR112023021426A2 (pt) Anticorpos de ligação a trop2 e usos dos mesmos
CO2020004200A2 (es) Anticuerpo monoclonal anti-il-5rα
BR112023022319A2 (pt) Anticorpos anti-tigit, anticorpos anti-cd96 e métodos de uso dos mesmos
CO2025003722A2 (es) Nueva proteína de fusión específica para cd137 y cd228